おすすめの製品
アッセイ
99%
フォーム
solid
mp
285 °C (dec.) (lit.)
保管温度
2-8°C
SMILES記法
Cl[H].NC(=N)Nc1ccc(cc1)C(O)=O
InChI
1S/C8H9N3O2.ClH/c9-8(10)11-6-3-1-5(2-4-6)7(12)13;/h1-4H,(H,12,13)(H4,9,10,11);1H
InChI Key
YETFLAUJROGBMC-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
4-Guanidinobenzoic acid hydrochloride is a guanidine derivative. Quality standard of 4-guanidinobenzoic acid hydrochloride has been investigated.
アプリケーション
4-Guanidinobenzoic acid hydrochloride may be used in ELISA inhibition assay of mouse antiserum. It may be used in the synthesis of human acrosin inhibitor 4′-acetaminophenyl 4-guanidinobenzoate hydrochloride.2
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
374962-5G:
374962-1G:
374962-BULK:
374962-VAR:
この製品を見ている人はこちらもチェック
S Ookawara et al.
European journal of clinical pharmacology, 51(2), 149-151 (1996-01-01)
Nafamostat mesilate, a potent protease inhibitor, is widely used for the treatment of pancreatitis, disseminated intravascular coagulation and as an anticoagulant in haemodialysis. However, hyperkalaemia associated with nafamostat mesilate has been reported. It is thought to be due to decreased
M K Ramjee et al.
Thrombosis research, 98(6), 559-569 (2000-07-19)
Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, is active against a number of the serine proteases involved in coagulation. This has been proposed as the basis of its anticoagulant activity. We investigated the reaction of Nafamostat with bovine pancreatic
I Midgley et al.
Xenobiotica; the fate of foreign compounds in biological systems, 24(1), 79-92 (1994-01-01)
1. The metabolic fate of N,N-dimethylcarbamoylmethyl 4-(4-guanidino[14C]benzoyloxy)phenylacetate methanesulphonate (14C-camostat mesylate) was investigated after i.v. administration to man (12-h infusion), and to rat and dog (bolus injection). 2. Renal excretion (mainly in 24 h) accounted for at least 80% dose in
Di-ya L, et al.
Chinese Pharmaceutical Journal, 3, 28-28 (2010)
S Muto et al.
British journal of pharmacology, 111(1), 173-178 (1994-01-01)
1. The present experiments were undertaken to determine the mechanism(s) of hyperkalaemia caused by nafamostat mesilate (NM), a serine-protease inhibitor. 2. We investigated the effects of luminal addition of two metabolites of NM, p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN), on
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）